01 Rising Global Diabetes Burden Increases Demand for Early Diabetic Retinopathy Screening The growing prevalence of diabetes worldwide is significantly increasing the demand for diabetic retinopathy screening, diagnosis, and treatment services. Sedentary lifestyles, unhealthy dietary habits, obesity, and an ageing population have contributed to a steady rise in diabetes cases, resulting in a larger patient pool at risk of vision-threatening complications. As diabetic retinopathy often progresses without noticeable symptoms in its early stages, healthcare providers are placing greater emphasis on routine retinal examinations for early detection and timely intervention. Governments and healthcare organisations are also expanding diabetes awareness programmes and preventive eye care initiatives to reduce avoidable blindness. The growing adoption of regular screening programmes is expected to improve diagnosis rates and increase demand for advanced ophthalmic imaging devices and treatment options over the coming years. In 2025, the International Diabetes Federation (IDF) reported that more than 589 million adults worldwide were living with diabetes, highlighting the urgent need for regular retinal screening and comprehensive diabetic eye care services to prevent vision loss.
02 Advancements in Retinal Imaging and Treatment Technologies Transform Patient Care Continuous technological advancements are reshaping the diabetic retinopathy market by improving the accuracy of diagnosis and expanding treatment options. Innovations such as artificial intelligence (AI)-assisted retinal screening, ultra-widefield retinal imaging, optical coherence tomography (OCT), and longer-lasting anti-VEGF therapies are enabling earlier disease detection and more personalised treatment. These technologies help clinicians identify retinal damage at earlier stages while reducing diagnostic time and improving patient outcomes. In addition, healthcare providers are increasingly integrating digital ophthalmology solutions into routine diabetes management, particularly in remote and underserved regions where access to specialists is limited. As healthcare systems continue to invest in advanced ophthalmic technologies, the adoption of innovative diagnostic and therapeutic solutions is expected to accelerate worldwide. In 2025, Topcon Healthcare expanded the deployment of its AI-enabled retinal screening solutions and cloud-based digital eye care platform, helping healthcare providers improve the early detection of diabetic retinopathy and streamline patient referrals for specialist treatment.
01 AI-Powered Screening Improves Early Detection and Expands Screening Access The integration of artificial intelligence (AI) into diabetic retinopathy screening is emerging as a significant growth driver for the Diabetic Retinopathy Market. AI-based systems can analyze retinal images rapidly and identify signs of diabetic retinopathy, helping healthcare providers detect disease at earlier stages and prioritize patients requiring specialist evaluation. These technologies can also support screening in primary care, community healthcare, and underserved areas where ophthalmologists may be limited. Creating demand for advanced diagnostic solutions.
02 Growing Ageing Population Increases the Risk of Diabetic Retinopathy The rapidly expanding ageing population is significantly contributing to the growth of the diabetic retinopathy market. Older adults are more susceptible to chronic diseases such as type 2 diabetes, making them more vulnerable to diabetes-related eye disorders, including diabetic retinopathy. As life expectancy continues to improve globally, healthcare systems are witnessing a growing demand for ophthalmic examinations, retinal imaging, and long-term disease management. Governments and healthcare providers are also investing in preventive eye care services to address the increasing burden of age-related vision disorders. This demographic shift is expected to create sustained demand for advanced diagnostic technologies and effective treatment options for diabetic retinopathy in the coming years. Positive Factor Estimated Impact (%) Growing global diabetic population +31% Increasing ageing population requiring eye care +25% Rising adoption of routine retinal screening +19% Higher demand for advanced retinal imaging technologies +15% Expanding availability of diabetic retinopathy treatments +10%
01 Limited Awareness and Low Screening Rates Delay Early Diagnosis of Diabetic Retinopathy Limited awareness of diabetic retinopathy remains a major challenge for the market, particularly in low- and middle-income countries where access to diabetes education and routine eye care is often limited. Many people living with diabetes are unaware that the disease can damage the retina long before noticeable vision problems develop. As a result, patients frequently delay comprehensive eye examinations until the condition has progressed to an advanced stage, reducing the effectiveness of available treatments. In addition, inadequate awareness among primary healthcare providers and unequal access to ophthalmology specialists can lead to delayed referrals and missed diagnoses. These factors increase the risk of irreversible vision loss while limiting the adoption of diagnostic imaging systems and treatment procedures. Strengthening public awareness campaigns, expanding diabetic eye screening programmes, and improving collaboration between diabetes specialists and ophthalmologists are essential to overcoming this restraint and improving patient outcomes. Negative Factor Estimated Impact (%) Delayed diagnosis due to low public awareness -29% Reduced participation in routine diabetic eye screening -24% Late initiation of treatment leading to vision complications -19% Underdiagnosis and delayed referrals in primary healthcare -16% Lower adoption of advanced retinal diagnostic technologies -12%
01 Advancements in AI-Powered Retinal Imaging and Digital Eye Care Create New Growth Opportunities Continuous advancements in diagnostic imaging technologies and treatment modalities are creating significant growth opportunities in the diabetic retinopathy market. Helping healthcare providers identify diabetic retinopathy before symptoms become severe. These technologies also support remote screening programmes, making quality eye care more accessible in underserved and rural communities. At the same time, and digital health platforms are enhancing disease monitoring and treatment planning. As healthcare systems continue to invest in digital ophthalmology and preventive eye care, the adoption of these advanced technologies is expected to accelerate worldwide.
01 High Cost of Advanced Diagnostic Technologies and Limited Access to Specialist Eye Care Challenge Market Growth The high cost of advanced retinal imaging systems and limited access to specialist eye care remain key challenges for the diabetic retinopathy market. Technologies such as optical coherence tomography (OCT), ultra-widefield retinal imaging, and AI-powered screening platforms require significant investment, making them less accessible for smaller hospitals and healthcare facilities, particularly in low- and middle-income countries. In addition, many rural and underserved regions face shortages of ophthalmologists and retinal specialists, resulting in delayed diagnosis and treatment. Although digital health and teleophthalmology are helping to bridge this gap, infrastructure limitations and inadequate reimbursement policies continue to slow widespread adoption. Addressing these challenges will require increased government funding, improved healthcare infrastructure, and broader deployment of affordable screening programmes to ensure timely access to diabetic eye care services.
May 2026 Bayer announced the acquisition of Perfuse Therapeutics in a deal worth up to USD 2.45 billion, strengthening its ophthalmology pipeline with PER-001, a Phase II therapy for diabetic retinopathy and glaucoma.
April 2026 The U.S. FDA approved extended dosing intervals of up to 20 weeks for Regeneron's EYLEA HD (aflibercept 8 mg) for diabetic macular edema, reducing treatment burden for patients with diabetic retinal diseases.
February 2025 Roche received U.S. FDA approval for Susvimo (ranibizumab injection) 100 mg/mL for diabetic retinopathy, expanding long-acting treatment options for retinal disease management.
January 2025 Regeneron Pharmaceuticals acquired Oxular Limited, gaining access to its sustained-release retinal drug delivery technologies to strengthen its ophthalmology and diabetic retinopathy portfolio.